Collectively these results demonstrate that MYCN is a key driver of tumorigenesis in neuroblastoma, suggesting that therapeutic efforts aimed at inhibiting its expression/activity should have an important clinical relevance. The gene discussed is MYCN; the disease is neuroblastoma.